Empagliflozin (Jardiance®)

DRUG4 trials

Sponsors

University Hospital Tuebingen, University of Chicago, ADIUM, University Medical Centre Ljubljana

Conditions

BioequivalanceDiabetes Type 2Kidney StonesType2 Diabetes Mellitus

Early Phase 1

SGLT2i in Kidney Stones

RecruitingNCT07055282

University of ChicagoKidney Stones

Start: 2025-11-20End: 2028-11-01Target: 32Updated: 2026-09-04

Phase 4

Empagliflozin Effect on Glucose Toxicity

WithdrawnNCT03437330

University Hospital TuebingenType2 Diabetes Mellitus

Start: 2021-10-27End: 2023-05-03Updated: 2024-05-16

The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes Mellitus

RecruitingNCT07771010

University Medical Centre LjubljanaDiabetes Type 2

Start: 2026-04-16End: 2028-07-31Target: 54Updated: 2026-08-18

Unknown Phase

Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions

CompletedNCT07479108

ADIUMBioequivalance

Start: 2024-11-29End: 2024-12-11Updated: 2026-03-18